La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ABIONYX Pharma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

ABIONYX Pharma ha un patrimonio netto totale di €7.9M e un debito totale di €1.6M, che porta il suo rapporto debito/patrimonio netto a 20.3%. Le sue attività totali e le sue passività totali sono rispettivamente €14.8M e €6.9M.

Informazioni chiave

20.3%

Rapporto debito/patrimonio netto

€1.61m

Debito

Indice di copertura degli interessi	n/a
Contanti	€4.10m
Patrimonio netto	€7.92m
Totale passività	€6.91m
Totale attività	€14.83m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

Jun 26

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Oct 12

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Jan 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €6.9M ) di ABNX superano le sue passività a breve termine ( €3.9M ).

Passività a lungo termine: Le attività a breve termine di ABNX ( €6.9M ) superano le sue passività a lungo termine ( €3.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ABNX ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ABNX si è ridotto da 143.4% a 20.3% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ABNX ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Si prevede che ABNX disponga di liquidità sufficiente per 5 mesi in base alle stime del flusso di cassa libero, ma da allora ha raccolto capitale aggiuntivo.

ABIONYX Pharma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Recent updates

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

New minor risk - Share price stability

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Consensus EPS estimates upgraded to €0.18 loss

Consensus EPS estimates upgraded to €0.23 loss

First half 2023 earnings released

New minor risk - Shareholder dilution

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

Price target increased to €5.50

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Consensus revenue estimates fall by 22%

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

Price target increased to €4.30

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

Investor sentiment improved over the past week

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

Investor sentiment improved over the past week

New 90-day low: €0.84

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

Investor sentiment improved over the past week

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

New 90-day high: €1.11

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

New 90-day low: €0.72

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane